Abstract Library

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4430 Long-term prognosis of parenchyma-sparing vs. oncologic resections for distal pancreatic non-functional neuroendocrine tumours ≤ 3cm: A real-world data study (CSPAC-NEN-5)

Introduction: Studies show that parenchyma-sparing resections (PSR) for small, non-functional pancreatic neuroendocrine tumours (NF-pNETs) provide long-term outcomes similar to oncologic resections (OR). However, these studies have not fully considered location-based differences in surgical approach and lymphatic drainage.

Conference:

Presenting Author: Li Z

Authors: Li Z, Ji S, Chen J, Xu X, Yu X,

Keywords: pancreatic neuroendocrine, parenchyma-sparing resection, recurrence-free survival,

#4409 The value of NETest 2.0 in stratifying patients with suspected NEN for formal diagnostic evaluation – Real-world data

Introduction: An unmet need in NEN diagnosis is better risk stratification for individuals with suspected disease (based on symptoms or imaging), enabling efficient identification of those needing further evaluation and tissue diagnosis, thus speeding the process and reducing costs. NETest 2.0, a biomarker based on a 51-gene mRNA panel, was developed for diagnosing neuroendocrine neoplasia (NEN).

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, at-risk population, NEN,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#4242 Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

Introduction: Everolimus and Sunitinib are often used consecutively for advanced, progressive, well-differentiated pancreatic neuroendocrine tumors (pNET), but to date no data on the optimal sequence is available.

Conference:

Presenting Author: Islam O

Authors: Islam O, van de Vyver G, Verslype C, Borbath I, Decaestecker J,

Keywords: pNEN, Everolimus, Sunitinib, mPFS, mOS, AEs,